Abstract | OBJECTIVE: METHODS: We retrospectively analyzed 108 patients with BPH who took dutasteride for more than 3 months from October 2009 to October 2011. The patients showed poor improvement in LUTS despite administration of alpha-1 blockers for more than 3 months; all had an International Prostate Symptom Score (IPSS) of eight or greater. We investigated changes in prostate-specific antigen and prostate volume and performed uroflowmetry and medical interviews to assess IPSS-QOL score and BPH impact index (BII). RESULTS: Mean prostate volume was 52.8 ± 22.2 mL, and the mean period of dutasteride administration was 284 ± 118 days. Prostate volume decreased 24.1% from baseline to 6 months after administration. Voiding symptoms and storage symptoms showed improvements with longer administration periods, but only nocturia showed no clear improvement. There was a 0.9-point decrease in BII after 6 months. There was no statistically significant association between the rate of prostate volume reduction and improvement in voiding and storage symptoms. CONCLUSION: Additional administration of dutasteride to patients with alpha-1 blocker-resistant BPH led to improvements in all voiding and storage symptoms except nocturia, and showed no correlation between the prostate volume reduction rates and improvement in LUTS.
|
Authors | Atsushi Sengiku, Yu Miyazaki, Harutake Sawazaki, Takeshi Takahashi, Keiji Ogura |
Journal | Lower urinary tract symptoms
(Low Urin Tract Symptoms)
Vol. 5
Issue 3
Pg. 159-63
(Sep 2013)
ISSN: 1757-5664 [Print] Australia |
PMID | 26663453
(Publication Type: Journal Article)
|
Copyright | © 2013 Wiley Publishing Asia Pty Ltd. |